Mark Smith

Head of Medicinal Chemistry

Stanford University

United States

Research Interests

Explore related searches

Professors in United States Professors in Organic Chemistry Organic Chemistry professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mark Smith is the Head of Medicinal Chemistry at Stanford University, located in the United States. His research focuses on the discovery and development of innovative therapeutic compounds, including prodrug technologies, kinase inhibitors, and antiviral agents. Recent publications highlight his work on targeting LRRK2 mutations associated with Parkinson's disease and the synthesis of novel nucleoside analogues.

Articles (10)

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Gavin Miller

Professor of Biological Chemistry

Keele University

UNITED KINGDOM

View details

Thomas J. Montine

Stanford University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mark Smith

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics.

Identification of highly potent and selective HTRA1 inhibitors

Chemical synthesis of 4′-thio and 4′-sulfinyl pyrimidine nucleoside analogues

Discovery of 1<i>H-</i>Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors

Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors.

Targeting <i>LRRK2</i> mutations in Parkinson's disease.

Design, chemical synthesis and antiviral evaluation of 2'-deoxy-2'-fluoro-2'-C-methyl-4'-thionucleosides.

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.

Nonbisphosphonate inhibitors of Plasmodium falciparum FPPS/GGPPS.

Peptidomimetics Therapeutics for Retinal Disease.

Collaborators (2)

Gavin Miller

Thomas J. Montine

Make your next move.